LOEP recommended as treatment option for patients at very high risk of hip fragility fractures

A recent position paper by a working group for the International Osteoporosis Foundation (IOF) and the European Society on the Clinical and Economic Aspects of Osteoporosis (ESCEO) defined the risk threshold for patients to be considered for available systemic and local treatments, including a Local Osteo-Enhancement Procedure (LOEP)*. The risk threshold varies by age and gender and can be determined using the FRAX risk assessment tool. The risk level of the potential treatment group for LOEP is the same as that being suggested for anabolic therapy. You can read more about the treatment selection algorithm here

An earlier IOF and ESCEO treatment guidance for European women with post-menopausal osteoporosis was published in Osteoporosis International.  That guidance document suggested patients at very high risk of hip fracture should be considered for LOEP treatment. That guidance document can be found here.

Physicians interested in learning more about LOEP should contact our medical affairs team.

*In the United States, the device used to perform AGN1 LOEP is investigational.